SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Decline in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totaling 175,963 shares, a drop of 31.0% from the March 31st total of 254,959 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 92,994 shares, the short-interest ratio is presently 1.9 days.

Insider Buying and Selling at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $5.00, for a total transaction of $87,365.00. Following the completion of the sale, the chief executive officer owned 3,646,967 shares of the company’s stock, valued at approximately $18,234,835. This trade represents a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 193,859 shares of company stock worth $943,777 over the last three months. 4.88% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SOPH. Alta Wealth Advisors LLC bought a new stake in SOPHiA GENETICS during the third quarter worth $6,708,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $49,000. Hodges Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS during the 1st quarter worth $2,157,000. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS during the 1st quarter worth $50,000. Finally, 1492 Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 8.4% during the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after buying an additional 17,406 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Price Performance

SOPH stock traded up $0.05 during midday trading on Thursday, reaching $5.33. The company had a trading volume of 75,763 shares, compared to its average volume of 170,241. SOPHiA GENETICS has a 1-year low of $2.59 and a 1-year high of $5.70. The stock has a 50 day moving average price of $4.80 and a 200-day moving average price of $4.77. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. The company has a market capitalization of $365.05 million, a price-to-earnings ratio of -10.45 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SOPH. Guggenheim raised their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Finally, BTIG Research raised their target price on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Hold” and an average price target of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.